141 related articles for article (PubMed ID: 38401695)
1. Filgrastim biosimilar (EP2006): A review of 15 years' post-approval evidence.
Gascón P; Harbeck N; Rapoport BL; Anderson R; Brueckmann I; Howe S; Aapro M
Crit Rev Oncol Hematol; 2024 Apr; 196():104306. PubMed ID: 38401695
[TBL] [Abstract][Full Text] [Related]
2. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
Blackwell K; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Harbeck N
Ann Oncol; 2017 Sep; 28(9):2272-2277. PubMed ID: 28637287
[TBL] [Abstract][Full Text] [Related]
3. Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
Harbeck N; Gascón P; Krendyukov A; Hoebel N; Gattu S; Blackwell K
Oncologist; 2018 Apr; 23(4):403-409. PubMed ID: 29317553
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
Blackwell K; Gascon P; Krendyukov A; Gattu S; Li Y; Harbeck N
Ann Oncol; 2018 Jan; 29(1):244-249. PubMed ID: 29091995
[TBL] [Abstract][Full Text] [Related]
5. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
Blackwell K; Semiglazov V; Krasnozhon D; Davidenko I; Nelyubina L; Nakov R; Stiegler G; Singh P; Schwebig A; Kramer S; Harbeck N
Ann Oncol; 2015 Sep; 26(9):1948-1953. PubMed ID: 26122726
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
[TBL] [Abstract][Full Text] [Related]
7. LA-EP2006: A Pegfilgrastim Biosimilar.
Hoy SM
BioDrugs; 2019 Apr; 33(2):229-232. PubMed ID: 30887256
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
Harbeck N; Lipatov O; Frolova M; Udovitsa D; Topuzov E; Ganea-Motan DE; Nakov R; Singh P; Rudy A; Blackwell K
Future Oncol; 2016 Jun; 12(11):1359-67. PubMed ID: 27020170
[TBL] [Abstract][Full Text] [Related]
9. Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery.
Marchesi F; Mengarelli A
Curr Med Chem; 2016; 23(21):2217-29. PubMed ID: 27183986
[TBL] [Abstract][Full Text] [Related]
10. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
[TBL] [Abstract][Full Text] [Related]
13. Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.
Harbeck N; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Blackwell K
Future Oncol; 2017 Jul; 13(16):1385-1393. PubMed ID: 28453299
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.
Sagara Y; Sato K; Fukuma E; Higaki K; Mizutani M; Osaki A; Takano T; Tokuda Y; Ohno S; Masuda N; Suzuki M; Saeki T
Jpn J Clin Oncol; 2013 Sep; 43(9):865-73. PubMed ID: 23858037
[TBL] [Abstract][Full Text] [Related]
16. Totality of the evidence at work: The first U.S. biosimilar.
Holzmann J; Balser S; Windisch J
Expert Opin Biol Ther; 2016; 16(2):137-42. PubMed ID: 26634611
[TBL] [Abstract][Full Text] [Related]
17. Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim.
Gascon P; Krendyukov A; Mathieson N; Natek M; Aapro M
BioDrugs; 2019 Dec; 33(6):635-645. PubMed ID: 31440986
[TBL] [Abstract][Full Text] [Related]
18. A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006).
Agarwala SS; Nagl U; Guo X; Bellon A; Heyn J; Dimova-Dobreva M; Shen YM; Schaffar G; Humphrey M; Mathieson N; Koptelova N; Gattu S
Curr Med Res Opin; 2022 Jun; 38(6):999-1009. PubMed ID: 35392751
[TBL] [Abstract][Full Text] [Related]
19. Tbo-Filgrastim: A Review in Neutropenic Conditions.
Blair HA; Scott LJ
BioDrugs; 2016 Apr; 30(2):153-60. PubMed ID: 27023705
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
